H. Lundbeck A/S

HLUN A

Equity

ISIN DK0061804697 / Valor 119252584

Nasdaq Copenhagen Equities (2024-11-20)

DKK 36.55+2.38%

H. Lundbeck A/S
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

H. Lundbeck A/S is a globally recognized pharmaceutical company headquartered in Denmark, with a specialized focus on developing treatments for brain diseases. Founded over a century ago by Hans Lundbeck, the company has established a significant presence in the neuroscience field, dedicating more than 70 years to the development and distribution of pioneering therapies. With a workforce of approximately 5,500 employees spread across more than 50 countries, Lundbeck operates production facilities in Denmark, France, and Italy, alongside research centers in Denmark and the US. The company's portfolio, which is registered in over 100 countries, reaches more than 8 million people daily. As of 2023, Lundbeck reported a revenue of DKK 19.9 billion, with its largest markets including the US, China, Canada, and several European countries, among others. The Lundbeck Foundation, holding about 70% of the company's shares, significantly supports medical research and educational initiatives with its annual grants.

Summarized from source with an LLMView SourceSector: Healthcare

Revenue Growth

H. Lundbeck A/S reported a revenue increase of 7% at constant exchange rates (CER) and 5% in Danish Krone (DKK), reaching DKK 5,288 million in the first quarter of 2024. This growth was primarily driven by strong performance in the U.S. and European markets.

Strategic Brands Performance

The revenue from H. Lundbeck A/S's strategic brands grew by 17% CER and 15% DKK, totaling DKK 3,759 million in Q1 2024. These brands now represent 71% of the company's total revenue, with notable contributions from Brintellix®/Trintellix®, Rexulti®, Abilify Maintena®/Asimtufii, and Vyepti®.

Adjusted EBITDA

H. Lundbeck A/S's adjusted EBITDA decreased to DKK 1,746 million, a decline of 2% CER and 5% DKK, due to lower adjusted gross margins and increased R&D costs. The adjusted EBITDA margin for Q1 2024 was 33.0%, down by 3.6 percentage points from the previous year.

Earnings Per Share

Adjusted earnings per share (EPS) for H. Lundbeck A/S in the first quarter of 2024 reached DKK 1.38, marking a 1% increase from the same period in the previous year. This growth was achieved despite fluctuations in stock valuation affecting the adjusted EBITDA.

Financial Outlook

H. Lundbeck A/S has maintained its financial guidance for 2024, expecting revenue growth of 7% to 10% at CER and adjusted EBITDA growth of 10% to 16% at CER. This outlook reflects the company's confidence in its strategic initiatives and market performance.

Summarized from source with an LLMView Source

Key figures

19.4%1Y

5.73%3Y

-25.5%5Y

Performance

25.1%1Y

29.8%3Y

31.6%5Y

Volatility